Bio-Path Holdings operates as an oncology-focused RNAi nanoparticle drug development company. They develop products using their DNAbilize platform, which protects DNA from destruction. Lead candidate prexigebersen is in Phase II trials for AML and myelodysplastic syndrome. Other candidates include BP1001-A (Phase I, solid tumors), BP1002 (Phase I, lymphoma/CLL) and BP1003 (Phase I, pancreatic cancer/non-small cell lung cancer/AML). The company was founded in 2007 and is based in Texas.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 0.1 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.1 |